PRCT | PROCEPT BioRobotics Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	91.47 - 94.34
52 Week Range	33.45 - 103.81
Beta	1.01
Implied Volatility	55.62%
IV Rank	19.61%
Day's Volume	425,438
Average Volume	921,084
Shares Outstanding	54,394,722
Market Cap	5,042,390,729
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2021-09-15

Valuation
Profitability
Growth
Health
P/E Ratio	-47.54
Forward P/E Ratio	-23.62
EPS	-1.95
1YR Price Target	50.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	626
Country	USA
Website	PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PRCT's peers: KIDS, NPCE, LUNG, SRDX, OFIX, RXST, SGHT, FNA, AXGN, TMCI, LIVN, SIBN, ITGR, CNMD, ESTA, QIPT, QTRX, VMD

*Chart delayed

Analyzing fundamentals for PRCT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see PRCT Fundamentals page.

Watching at PRCT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PRCT Technicals page.